Macrocyclic GBCAs in nonenhanced T1 signal intensity pediatric brain tissue.
Multiple administration of macrocyclic gadolinium-based contrast agents (GBCAs) does not result in measurable increase in signal intensity (SI) in key brain regions among children, according to a study published in Radiology.
Researchers from Germany performed a retrospective study to determine whether SI in T1 sequences as a potential indicator of gadolinium deposition increases after repeated administration of GBCAs gadoteridol and gadoterate meglumine in a pediatric cohort.
Twenty-four children with brain tumors, aged 5 to 18, were included in the study. All children underwent nine or more contrast material–enhanced brain MR imaging studies. Twenty-four control patients with nonpathologic MR neuroimaging findings and no GBCA administration were also included.
The researchers measured SI on unenhanced T1-weighted MR images for five regions of interest (ROIs):
• Dentate nucleus (DN)
• Pons
• Substantia nigra (SN)
• Pulvinar thalami
• Globus pallidus (GP)
There was a mean of 14.2 GBCA administrations. No significant differences in mean SI for any ROI and no group differences were found when DN-to-pons and GP-to-pulvinar ratios were compared.
Mean signal-intensity ratios:
The researchers concluded that multiple intravenous administrations of these macrocyclic GBCAs in children were not associated with a measurable increase in SI in T1 sequences as an indicator of brain gadolinium deposition detectable by using MR imaging. However, additional imaging and pathologic studies are needed to confirm the findings.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
November 14th 2023Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.